Evommune, Inc. Increase Decrease In Operating Lease Liability
Evommune, Inc. (EVMN) reported Increase Decrease In Operating Lease Liability of -$537.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- Evommune, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$344.00K.
- Evommune, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$193.00K.
- Evommune, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$139.00K.
- Evommune, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$175.00K.
- Evommune, Inc. increase decrease in operating lease liability for fiscal 2025 was -$730.00K.
- Evommune, Inc. increase decrease in operating lease liability for fiscal 2024 was -$769.00K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$344.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$537.00K 10-Q · filed 2026-08-06 | -$676.00K derived: sum of 3 quarters · filed 2026-08-06 | -$851.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$193.00K 10-Q · filed 2026-05-07 | -$332.00K derived: sum of 2 quarters · filed 2026-05-07 | -$507.00K derived: sum of 3 quarters · filed 2026-05-07 | -$717.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$314.00K derived: sum of 2 quarters · filed 2026-03-05 | -$524.00K derived: sum of 3 quarters · filed 2026-08-06 | -$730.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-12-11 | -$385.00K derived: sum of 2 quarters · filed 2026-08-06 | -$591.00K 10-Q · filed 2025-12-11 | -$793.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$210.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$416.00K 10-Q · filed 2026-08-06 | -$618.00K derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-03-31 | -$206.00K 10-Q · filed 2026-05-07 | -$408.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$202.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$769.00K 10-K · filed 2026-03-05 | ||
| 2024-09-30 | -$567.00K 10-Q · filed 2025-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |